ILMN vs MYGN
ILMN: Illumina provides the essential genetic sequencing and array platforms that power modern genomic research and clinical diagnostics. MYGN: Myriad Genetics is a genetic testing company focused on providing actionable insights for cancer risk, reproductive health, and mental health clinical decisions.
Side-by-side fundamentals
| Metric | ILMN | MYGN | Edge |
|---|---|---|---|
| Price as of 2026-10-20 close | $267.93 | $5.54 | |
| Market cap | $40.5B | $530M | |
| P/E as of 2026-10-20 | 49.99 | n/a | |
| Net margin FY2025, SEC XBRL | +19.6% | -44.4% | ILMN higher |
| Gross margin FY2025, SEC XBRL | +66.1% | +69.9% | MYGN higher |
| Operating margin FY2025, SEC XBRL | +18.6% | -47.0% | ILMN higher |
| ROE FY2025, SEC XBRL | +31.2% | -99.4% | ILMN higher |
| ROA FY2025, SEC XBRL | +12.8% | -51.8% | ILMN higher |
| Debt / equity filed borrowings, leases excl., balance sheet 2026-06-30 | n/a | 0.40 | |
| Revenue growth (YoY) FY2025, SEC XBRL | -0.7% | -1.6% | ILMN higher |
| Revenue CAGR (3y) SEC XBRL | -1.4% | +6.7% | MYGN higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-02 | 1.01 | 1.14 | |
| 1-year return as of 2026-10-20 close | +169.3% | -29.9% | ILMN higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.